...
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice
【24h】

Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice

机译:药物相互作用与4-β-杂志:对临床实践的文学和影响审查

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Aprepitant and its parenteral formulation fosaprepitant are widely used for the prevention of chemotherapy-induced nausea and vomiting. Aprepitant exerts modest inhibitory effect on CYP3A4 and modest inductive effect on CYP2C9 substrates such as some antineoplastics and multiple other medications. This article is aimed to provide pharmacists and other healthcare professionals with an updated summary of drug–drug interactions of aprepitant/fosaprepitant and implications for clinical practice. Method We reviewed publications reporting drug–drug interactions between aprepitant/fosaprepitant and other medications. Results Coadministration of aprepitant with antineoplastics or opiods may result in significant elevations in the serum levels of the agents metabolized via CYP3A4, with the best documentation for cyclophosphamide, ifosfamide, erlotinib and oxycodone. These alterations did not translate into adverse outcomes and/or necessitate dosing adjustments. The levels of warfarin were significantly decreased by aprepitant requiring prolonged monitoring after discontinuation of aprepitant. Among direct oral anticoagulants, a theoretical interaction between aprepitant and rivaroxaban or apixaban exists. Interactions between aprepitant and quetiapine or diltiazem or sirolimus required dose reductions to avoid adverse outcomes. The intravenous route had a weaker inhibitory effect on CYP3A4 than the oral pathway. Conclusion The evidence on drug interactions of aprepitant with other medications is limited, and the impact on therapeutic outcomes remains to be determined. The intravenous regimen may be a preferred option. As utilization of aprepitant is expanding, practitioners and patients need to be educated about the potential for drug interactions and a need for careful monitoring of patients concurrently receiving aprepitant and CYP2C9 or CYP3A4 substrates, especially those with a narrow therapeutic window.
机译:目的阿普瑞平及其胃肠外制剂福萨普瑞平被广泛用于预防化疗引起的恶心和呕吐。阿普瑞平对CYP3A4具有适度的抑制作用,对CYP2C9底物(如一些抗肿瘤药物和多种其他药物)具有适度的诱导作用。本文旨在为药剂师和其他医疗保健专业人员提供阿普雷帕坦/福萨雷帕坦的药物-药物相互作用的最新总结,以及对临床实践的影响。方法我们回顾了报道阿普瑞平/福萨瑞平和其他药物之间药物-药物相互作用的出版物。结果阿普瑞平与抗肿瘤药物或阿片类药物合用可能导致通过CYP3A4代谢的药物的血清水平显著升高,其中环磷酰胺、异环磷酰胺、厄洛替尼和羟考酮的记录最好。这些改变没有转化为不良结果和/或需要调整剂量。停药后,需要长期监测的阿普瑞汀可显著降低华法林水平。在直接口服抗凝剂中,理论上阿普瑞平与利伐沙班或阿哌沙班之间存在相互作用。阿普瑞平与奎硫平、地尔硫卓或西罗莫司之间的相互作用需要减少剂量以避免不良后果。静脉途径对CYP3A4的抑制作用弱于口服途径。结论阿普雷帕坦与其他药物相互作用的证据有限,对治疗结果的影响仍有待确定。静脉注射可能是首选方案。随着安普利坦的使用范围不断扩大,从业者和患者需要了解药物相互作用的可能性,并需要仔细监测同时服用安普利坦和CYP2C9或CYP3A4底物的患者,尤其是治疗窗口狭窄的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号